Methylnortestosterone is a synthetic anabolic steroid derived from nandrolone . This substance is also called trestolone . Methylnortestosterone is a vague name and can be applied to other steroids. It has some level of bioavailability when administered orally, but it was used only as an injection or a transdermal gel.
Methylnortestosterone is an anabolic steroid with mild androgenic and estrogenic properties. The activity of the steroid is increased due to methylation , the resistance to metabolism in the liver increases and the binding of binding proteins in the blood decreases. Methylnortestosterone has a short half-life, but it hardly binds to binding proteins.
According to research in 1963, it is 3.5-23 times more anabolic than testosterone, but 3-6 times more androgenic . According to a 1998 study on primates, anabolicity is 10 times higher than that of testosterone, and androgenicity is only twice as high, however, methylnortestosterone is more androgenic due to its better binding to androgen receptors, compared to testosterone, nandrolone and dihydrotestosterone .
Methylnortestosterone acetate was first described in 1963. The early 1960s were the heyday of AAS research. For 40 years, methylnortestosterone has not been produced due to the lack of financial investments. However , on October 30, 2000, Schering announced that it would begin research on the drug as male contraceptive and hormone replacement therapy.
The Schering hoped metilnortestosteron will have the beneficial properties of testosterone without any problems with androgens . Methylnortestosterone attracted the manufacturer not so much by its activity as by the ability to duplicate the effect of testosterone without affecting the prostate.
Prostate cancer and prostate adenoma are common problems among men in the United States, and both diseases are accelerated by the administration of androgens. This usually manifests itself during hormone replacement therapy in the elderly. They concluded that the use of metilnortestosterona in this case more than acceptable . It has also been researched as a male contraceptive.
Methylnortestosterone is not yet available as a pharmacy drug.
Methylnortestosterone is a modified form of nandrolone . It features the addition of a methyl group at the 7-alpha position to increase steroid activity and reduce androgenicity . Methylnortestosterone acetate is methylnortestosterone bound to the acetate ester via the 17-beta hydroxyl group, which allows the drug to be active after injection. Info: https://anabolicmenu.ws/global-anabolic-tres-50/
Estrogenic side effects:
Methylnortestosterone aromatizes and is converted to estrogen with a high level of biological activity (7-alpha-methyl-estradiol). As a result, it is a mildly estrogenic steroid. Gynecomastia is possible, especially with high doses. At the same time, water retention and the growth of body fat can be problematic. Sensitive people can keep estrogen in check by using an antiestrogen such as tamoxifen. It can be alternated with aromatase inhibitors such as aridimidex, which are more effective in controlling estrogen. Aromatase inhibitors, however, can be quite expensive and can have negative effects on blood lipids.
It should be noted that there was no mention of gynecomastia in any of the clinical studies. Estrogenicity is not an issue at therapeutic dosages. It should also be noted that studies have shown that methylnortastosterone binds strongly to progesterone receptors.
It has moderate progestogenic activity. The side effects of progesterone are similar to those of estrogen , however, progestins increase the stimulating effect of estrogens on breast tissue growth. The interaction is so strong that the gynecomycete can appear with the help of progestins without increasing estrogen levels. The use of anti-estrogens can alleviate gynecomastia caused by AAS.
Androgenic Side Effects:
Methylnortestosterone is classified as an anabolic, but androgenic side effects are still possible. This can be increased oily skin, acne, hair growth on the body and face. High doses are likely to cause them. Anabolic steroids can worsen male-pattern hair loss. Sensitive people may exchange this steroid for nandrolone decanoate . Women additionally need to be aware of the potential virilizing effects of AAS. This may include a hardened voice, irregular periods, changes in skin texture, facial hair growth, and an enlarged clitoris. Methylnortestosterone does not react with 5a-reductase and its androgenicity cannot be altered by concurrent administration of finasteride or dutasteride . Greater androgenic activity, in comparison with nandrolone , allows males to maintain libido on the course.
Side effects ( hepatotoxicity ):
Methylnortestosterone is not alkylated in the 17-alpha position, therefore it does not have hepatotoxic properties.
Side effects (cardiovascular system):
AAS can have harmful effects on blood cholesterol. This may be a decrease in the level of “good” HDL, a shift in the balance towards the risk of atherosclerosis. The relative effect of AAS on lipids depends on dose, route of administration, type of steroid, and level of resistance to hepatic metabolism. Methylnortestosterone has a moderate effect on hepatic cholesterol management due to its aromatizing structure and route of administration. AAS can have a negative effect on blood pressure and triglycerides, reduce vascular endothelial relaxation, provoke ventricular hypertrophy, which potentially increases the risk of cardiovascular disease and heart attack. To reduce the stress on the cardiovascular system, it is recommended to minimize the consumption of saturated fat, cholesterol and simple carbohydrates during the course of the AAS. The use of supplements such as fish oil, lipid stable or similar products is recommended .
Suppression of testosterone:
All AAS, in doses required for muscle building, suppress endogenous testosterone production. Without the intervention of substances stimulating the production of testosterone, testosterone will return to normal levels within 1-4 months after the course. Note that with prolonged hypogonadotropic hypogonadism may develop into secondary hypogonadism and require medical attention.
The aforementioned side effects are not all effects that can be. Read the “Side Effects” chapter in this book for a detailed study.
Reception (for men):
Methylnortestosterone has also been introduced as a pharmaceutical product. It is a relatively potent steroid, so the effective dose may be small. If we see a product with acetate ester, then the required dose will be 10-20mg every two to three days. It can be combined with many different steroids for different purposes.
Reception (for women):
Methylnortestosterone has also been introduced as a pharmaceutical product.